A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

NCT07522801 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

93

Enrollment

OTHER

Sponsor class

Conditions

LAL

Interventions

DRUG: Venetoclax + Tofacitinib
DRUG: Venetoclax+ Everoliumus +Enrylaze
DRUG: Venetoclax + 5 Azacitidine

Sponsor

Philippe ROUSSELOT